Debbie Hart is CEO and president of BioNJ.
We asked her about how patients and the innovation economy could be under threat from proposed regulation:
“New Jersey is a hotbed of medical innovation, with many groundbreaking treatments being developed right here at home. Sadly, some proposed policies threaten those drugs from getting to the patients who need them. Methods that determine drug access based on cost alone — such as the one the Institute for Clinical and Economic Review advocates for — not only take treatments away from those who need them, they threaten innovation. ICER is not the answer. Policy proposals must ensure that patients can access medicines when they need them. This includes capping out-of-pocket costs for seniors in Medicare Part D. See bionj.org/protect-medical-innovation for details.”